# Twist Bioscience Corporation (TWST) Stock Analysis: Exploring Growth Potential with 10.84% Upside

- Link: https://www.directorstalkinterviews.com/twist-bioscience-corporation-twst-stock-analysis-exploring-growth-potential-with-10-84-upside/4121245017
- Published: 2026-03-17T11:14:07+00:00
- Author: Madison Wilson

Twist Bioscience Corporation (NASDAQ: TWST), headquartered in South San Francisco,
California, is a prominent player in the healthcare sector, specializing in the 
diagnostics and research industry. With a market capitalization of $2.76 billion,
Twist Bioscience is renowned for its innovative approach in manufacturing and selling
synthetic DNA-based products. These products are integral to a wide array of applications,
including therapeutics, diagnostics, and data storage, making it a compelling choice
for investors interested in biotechnology.

At a current price of $45.01, TWST’s stock has seen a modest change of 1.73 (0.04%),
reflecting stability in its trading patterns. Over the past year, the stock has 
fluctuated between $24.16 and $54.92, indicating potential volatility but also opportunities
for growth. Analysts have set a target price range between $36.00 and $58.00, with
an average target of $49.89, suggesting a potential upside of 10.84% from its current
level.

Twist Bioscience’s revenue growth stands at an impressive 16.90%, which underscores
the company’s expanding market presence and its ability to capitalize on the increasing
demand for synthetic DNA products. However, the company faces challenges typical
of a rapidly growing biotech firm. Its forward P/E ratio is -23.88, indicating that
profitability is still on the horizon. The company’s EPS is at -1.27, and it has
a return on equity of -16.79%, pointing towards ongoing investments in research 
and development to fuel future growth.

The absence of a dividend yield, combined with a payout ratio of 0.00%, suggests
that Twist Bioscience is reinvesting its earnings to enhance its product offerings
and expand its market reach. This strategy aligns with the company’s focus on long-
term growth rather than short-term shareholder returns.

In terms of technical indicators, the stock’s 50-day moving average is $44.93, while
the 200-day moving average is significantly lower at $34.62, indicating a positive
trend in the stock’s performance. However, the Relative Strength Index (RSI) of 
29.35, coupled with a MACD of -0.28, suggests that the stock might be oversold, 
presenting a potential buying opportunity for investors.

Analyst sentiment towards TWST is predominantly optimistic, with eight buy ratings
and two hold ratings, and no sell ratings. This positive outlook is supported by
the company’s strategic collaboration with bitBiome Inc., which could enhance its
capabilities in synthetic DNA applications.

Twist Bioscience continues to innovate with its offerings, such as synthetic SARS-
CoV-2 RNA reference sequences and various respiratory viral controls, crucial during
the ongoing global health challenges. These innovative solutions position Twist 
Bioscience as a vital player in the diagnostics and research industry, with the 
potential to drive significant advancements in healthcare and beyond.

For investors seeking exposure to the biotechnology sector, Twist Bioscience represents
an intriguing opportunity. While there are inherent risks associated with investing
in a company still navigating towards profitability, the potential rewards, as indicated
by the projected upside and the company’s strategic initiatives, make TWST a stock
worth considering for those with an appetite for growth-oriented investments.

Share on: